Statin myotoxicity is associated with changes in the cardiopulmonary function

Area of Science:

• Metabolic Medicine
• Exercise Physiology
• Pharmacology

Background:

• Muscle toxicity is a known side effect of lipid-lowering therapies, particularly statins.
• Pathological findings in statin-induced myopathy suggest impaired fatty acid oxidation.
• Exhaled gas analysis is a non-invasive method to assess substrate utilization, including lipid oxidation.

Purpose of the Study:

• To investigate if muscle toxicity from lipid-lowering therapy is linked to abnormalities in lipid oxidation.
• To compare lipid oxidation in patients with a history of statin-associated myositis versus healthy controls.

Main Methods:

• Exhaled gas analysis was performed in the fasted state on 11 patients post-statin myositis and 16 healthy controls.
• Controls were measured both on and off statin therapy.
• Key metrics included anaerobic threshold (AT), maximal oxygen consumption (VO2max), ventilatory efficiency (VE/VCO2), and respiratory exchange ratio (RER).

Main Results:

• Post-myositis patients exhibited a depressed anaerobic threshold (AT) compared to controls.
• Fasting respiratory exchange ratio (RER) was abnormally increased in post-myositis patients off statins.
• Healthy controls showed increased RER when on statins, indicating decreased lipid oxidation.

Conclusions:

• Abnormal lipid oxidation may predispose certain individuals to statin-associated muscle toxicity.
• Exhaled gas analysis can reveal metabolic alterations related to statin myopathy.
• Further research is warranted to elucidate the precise mechanisms linking lipid metabolism and statin-induced muscle damage.